Research to real-world application: experts weigh in on the underuse of anticoagulants

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Anticoagulant therapy significantly reduces stroke and thromboembolic events in nonvalvular atrial fibrillation (NVAF).
• Despite proven benefits, anticoagulants are underprescribed in real-world clinical practice.
• Standardized risk assessments, recommended by guidelines, are not consistently utilized.

Purpose of the Study:

• To identify factors contributing to the underuse of anticoagulants in patients with nonvalvular atrial fibrillation.
• To explore potential strategies for improving the appropriate prescription rates of anticoagulant therapies.

Main Methods:

• Review of clinical guidelines and real-world data on anticoagulant prescribing patterns.
• Analysis of patient characteristics, comorbidities, and physician-related factors influencing treatment decisions.
• Examination of barriers such as bleeding concerns, monitoring feasibility, and patient access to care.

Main Results:

• Underprescription is multifactorial, involving patient-specific issues (comorbidities) and physician concerns (bleeding risk, monitoring challenges).
• Warfarin prescribing is particularly affected by perceived difficulties in follow-up care.
• Patient-related factors like fear of treatment and healthcare system access also contribute to underuse.

Conclusions:

• Addressing anticoagulant underuse requires a multifaceted approach.
• Strategies include enhancing physician and patient education, implementing medical therapy management, improving care coordination, and optimizing monitoring and follow-up protocols.
• These interventions aim to increase the appropriate utilization of anticoagulants in NVAF patients, thereby reducing stroke risk.